NEW YORK (360Dx) – Infectious and inflammatory disease diagnostics firm MeMed today announced it completed a new round of financing that totaled more than $70 million.

The financing will go toward driving market adoption of MeMed's immune system-based test for distinguishing between bacterial and viral infections called MeMed BV. The funds will also be used to complete development, upscale manufacturing, and clearance of another technology called MeMed Key, a point-of-care protein measurement platform, and to expand the company's pipeline of tests.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.